# OnCo record catumaxomab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/catumaxomab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "catumaxomab" ;
  schema:name "Catumaxomab"@en ;
  schema:alternateName "Removab (2009 to 2017)"@en, "Korjuny" ;
  schema:description "Catumaxomab (Korjuny) is an antibody infused into the abdominal cavity to control malignant ascites, the build-up of fluid caused by cancers such as ovarian and stomach cancer, in people whose other treatments have stopped working."@en ;
  schema:url <https://onco.cc/drugs/catumaxomab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Catumaxomab> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny> ;
  onco:status "approved" ;
  onco:tag "ema-list", "supportive" ;
  onco:modality "Trifunctional bispecific antibody (EpCAM x CD3, rat-mouse hybrid)" ;
  onco:approval "EU 2009: Malignant ascites in EpCAM-positive carcinomas when standard therapy is unavailable (Removab; withdrawn 2017)", "EU 2025: Intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas not eligible for further systemic therapy (Korjuny)" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/epcam/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/lindis-biotech/> ;
  onco:trials <https://onco.cc/trials/nct00377429/>, <https://onco.cc/trials/nct00189345/>, <https://onco.cc/trials/nct00563836/> .